A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

Abstract

Summary Deferasirox is a once‐daily, oral iron chelator developed for treating transfusional iron overload. Preclinical studies indicated that the kidney was a potential target organ of toxicity. As patients with sickle cell disease often have abnormal baseline renal function, the primary objective of this randomised, open‐label, phase II trial was to evaluate the safety and tolerability of deferasirox in comparison with deferoxamine in this population. Assessment of efficacy, as measured by change in liver iron concentration (LIC) using biosusceptometry, was a secondary objective. A total of 195 adult and paediatric patients received deferasirox ( n = 132) or deferoxamine ( n = 63). Adverse events most commonly associated with deferasirox were mild, including transient nausea, vomiting, diarrhoea, abdominal pain and skin rash. Abnormal laboratory studies with deferasirox were occasionally associated with mild non‐progressive increases in serum creatinine and reversible elevations in liver function tests. Discontinuation rates from deferasirox (11·4%) and deferoxamine (11·1%) were similar. Over 1 year, similar dose‐dependent LIC reductions were observed with deferasirox and deferoxamine. Once‐daily oral deferasirox has acceptable tolerability and appears to have similar efficacy to deferoxamine in reducing iron burden in transfused patients with sickle cell disease.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 23

1. 1.

   Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine. 1998;339:5-11.

   Not in our library10.1056/nejm199807023390102

2. 2.

   Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Seminars in Hematology. 2001;38(Suppl. 1):30-36.

   Not in our library10.1016/s0037-1963(01)90058-7

3. 3.

   Brittenham GM, Farrel DE, Harris JW, Feldman ES, Danish EH, Muir WA, Tripp JH, Bellon EM. Magnetic susceptibility measurement of human iron stores. New England Journal of Medicine. 1982;307:1671-1675.

   Not in our library10.1056/nejm198212303072703

4. 4.

   Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. American Journal of Hematology. 1993;42:81-85.

   Not in our library10.1002/ajh.2830420116

5. 5.

   Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Dfaffer C, Marks P, Alberti D. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107:3455-3462.

   Not in our library10.1182/blood-2005-08-3430

6. 6.

   Fischer R, Harmatz P, Nielsen P. Does liver biopsy overestimate liver iron concentration? Blood. 2006;108:1775-1776.

   Not in our library10.1182/blood-2006-03-013482

7. 7.

   Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematologica. 1996;95:26-36.

   Not in our library10.1159/000203853

8. 8.

   Hagar RW, Vichinsky EP. Major changes in sickle cell disease. Advances in Pediatrics. 2000;47:249-272.

   Not in our library

9. 9.

   Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. The Journal of the American Medical Association. 1983;249:1743-1745.

   Not in our library

10. 10.

    Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101:91-96.

    Not in our library10.1182/blood-2002-06-1704

11. 11.

    Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J, Shah AK, Mankad VN. Investigators of the Cooperative Study of sickle cell disease. Causes of death in sickle cell disease: an autopsy study. British Journal of Haematology. 2003;123:359-365.

    Not in our library10.1046/j.1365-2141.2003.04594.x

12. 12.

    McLaren GD, Muir WA, Kellermeyer RW. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Critical Reviews in Clinical Laboratory Sciences. 1983;19:205-266.

    Not in our library10.3109/10408368309165764

13. 13.

    Management and Therapy of Sickle Cell Disease. 2002.

    Not in our library

14. 14.

    Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.

    Not in our library

15. 15.

    Porter JB. Practical management of iron overload. British Journal of Haematology. 2001;115:239-252.

    Not in our library10.1046/j.1365-2141.2001.03195.x

16. 16.

    Schrier SL, Angelucci E. New strategies in the treatment of thalassemias. Annual Review of Medicine. 2005;56:157-171.

    Not in our library10.1146/annurev.med.56.082103.104718

17. 17.

    Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. Journal of Pediatrics. 1994;125:909-911.

    Not in our library10.1016/s0022-3476(05)82006-2

18. 18.

    Tanner JM. Fetus into Man: Physical Growth from Conception to Maturity. 1978.

    Not in our library

19. 19.

    Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine. 2005;353:2769-2778.

    Not in our library10.1056/nejmoa050460

20. 20.

    Treadwell MJ, Law AW, Sung J, Hackney-Stephens E, Quirolo K, Murray E, Glendenning GA, Vichinsky E. Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatric Blood and Cancer. 2005;44:500-507.

    Not in our library10.1002/pbc.20290

21. 21.

    Vanorden HE, Hagemann TM. Deferasirox — an oral agent for chronic iron overload. Annals of Pharmacotherapy. 2006;40:1110-1117.

    Not in our library10.1345/aph.1g566

22. 22.

    Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L, Williams R, Louie L, Lee PD, Harmatz P. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. American Journal of Hematology. 2005;80:70-74.

    Not in our library10.1002/ajh.20402

23. 23.

    Wanko SO, Telen MJ. Transfusion management in sickle cell disease. Hematology/Oncology Clinics of North America. 2005;19:803-826.

    Not in our library10.1016/j.hoc.2005.07.002

Cited by papers we hold 2

• Iron Chelators in Treatment of Iron Overload · 2022
  No notice
• Renal clearable nanochelators for iron overload therapy · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.